Chirality Biosciences, Inc.

Chirality Biosciences is dedicated to advancing pharmaceuticals through innovative chiral separation technology, aimed at enhancing the purity and efficacy of active pharmaceutical ingredients (APIs) while minimizing adverse effects. Chirality Biosciences, Inc. specializes in pioneering the development and commercialization of advanced pharmaceuticals. Founded in 2023, the company is headquartered in Farmingdale, US.

Arielle Gabalski, the founder, has a history of involvement in the pharmaceutical industry. The company recently completed its first deal and raised USD 3. 105 mn in a Seed round on October 17, 2025, with investments from Pioneer Fund and others. This funding brings the total amount raised by Chirality to USD 3.

105 mn, with a current company valuation of USD 13. 264 mn. Chirality Biosciences specializes in the development and commercialization of advanced pharmaceuticals utilizing proprietary chiral separation technology. This technology enables the production of active pharmaceutical ingredients (APIs) with higher purity and reduced side effects, addressing common issues associated with traditional drug formulations such as brain fog, nausea, and inflammation.

The company targets scientists, pharmaceutical manufacturers, and operators aiming to modernize their production processes. By providing safer and more effective drugs, Chirality facilitates faster paths to market for life-saving medications, poised to serve global markets with a strong demand for innovative pharmaceutical solutions. Chirality Biosciences generates revenue through strategic partnerships and direct sales of its proprietary technology and services to pharmaceutical clients. Primarily operating in a B2B model, the company collaborates with manufacturers to provide customized chiral separation services or technologies for drug development processes.

These partnerships often involve contractual agreements that may include service fees based on API production volume or specific technologies licensed. The flagship offerings emphasize purity and reduced side effects, likely commanding premium pricing given their innovative production approach. Chirality Biosciences plans to leverage the recent Seed funding of USD 3. 105 mn to support the development and launch of new products utilizing its proprietary chiral separation technology.

The company aims to expand its market reach, particularly targeting regions with high demand for innovative pharmaceutical solutions. Specific geographic markets targeted for expansion have not been disclosed, but the company is well-positioned to enter global markets by 2026.